Saturday 17 October 2026 Export GEHC’s income statement to Excel — free account

GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 billion, up 4.84% from fiscal 2024. In the quarter to June 2026, revenue grew 5.75%, EPS grew 17.0%, free cash flow grew 750.0% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for three consecutive years, revenue growth for five; insiders bought in the last twelve months.

69.57 0.78 −1.11%

Follow GEHC

Alert me

Market cap: $31.8B
P/E: 16.0×
Fwd P/E: 14.4×
Dividend yield: 0.26%
F-score: 4/9
Altman Z: 1.96
Beneish M: −2.33
Dividend safety: 74/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total buys 6.42

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	2	6	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.61%

Capital & Financial Ratios $m

Market Cap 31,780.00

Revenue 21,267.00

Net Income 2,051.00

Free Cash Flow 1,579.00

Net Debt 9,427.00

Current Ratio 1.26

Debt/Equity 1.05

P/E ratio 15.96

Fwd P/E 14.40

P/S ratio 1.48

P/B ratio 2.87

Past 5Y EPS Growth (31.63%)

This Y EPS Growth 7.28%

Next Y EPS Growth 10.37%

Next Y revenue growth 5.32%

Next 5Y EPS Growth 9.59%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 29.34%

10-year low 10-year high

P/S against its own 10 years 11.15%

10-year low 10-year high

P/B against its own 10 years 11.12%

10-year low 10-year high

EV/Sales against its own 10 years 13.14%

10-year low 10-year high

EV/FCF against its own 10 years 41.16%

10-year low 10-year high

Dividends

Payout Ratio 0.04

Annual Dividend Rate 0.18

Annual Dividend Yield 0.26%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.15	0.04 0.04 0.04 0.04
2025	0.14	0.04 0.04 0.04 0.04
2024	0.12	0.03 0.03 0.03 0.03
2023	0.09	0.03 0.03 0.03

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2,504	2,889	4,512	2,105
Receivables	3,557	3,566	3,955	3,881
Inventory	1,960	1,939	2,234	2,483
Other	389	532	726	793
	9,410	9,901	12,501	10,497

	2023	2024	2025	Q'26
Payables	2,947	3,035	3,250	3,231
ST’ Debt	2,524	3,023	2,174	1,441
Other	3,411	3,495	3,682	3,629
	8,981	9,553	9,105	8,302

Compound Annual Growth %

	10y	5y	3y
Sales	—	3.74%	3.99%
Cash Flow	—	(5.37%)	(2.35%)
Earnings	—	(31.53%)	2.84%
Book Value	—	(6.77%)	3.53%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	5,131	5,295	—	—	—
’25	4,777	5,007	5,143	5,698	20,625
’24	4,650	4,839	4,863	5,320	19,672
’23	4,707	4,817	4,822	5,206	19,552
’22	4,343	4,484	4,576	4,938	18,341
’21	—	—	—	—	17,585
’20	—	—	—	—	17,164

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	290	168	—	—	—
’25	250	94	593	1,050	1,987
’24	419	(119)	742	913	1,955
’23	468	(67)	650	1,050	2,101
’22	468	(19)	622	1,063	2,134
’21	—	—	1,618	(11)	1,607
’20	—	—	—	2,618	2,618

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	112	68	—	—	—
’25	98	8	483	916	1,505
’24	274	(183)	652	811	1,554
’23	325	(136)	570	956	1,715
’22	371	(78)	548	987	1,828
’21	—	—	1,459	(85)	1,374
’20	—	—	—	2,375	2,375

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.85	1.24	—	—	—
’25	1.23	1.06	0.98	1.29	4.55
’24	0.81	0.93	1.02	1.57	4.34
’23	0.41	0.91	0.82	0.88	3.03
’22	0.89	1.10	1.09	1.22	4.22
’21	—	—	—	—	5.05
’20	—	—	—	—	30.45

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	53.00	53.50	71.31	57.65	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	66.28	87.83	94.55	94.80
People
People	Employees	—	—	—	—	—	51,000	50,000	51,000	53,000	54,000
	Revenue/emp, $m	—	—	—	0.00	0.00	0.34	0.37	0.38	0.37	0.38
Income, $m
Income, $m	Revenue	—	—	—	16,633	17,164	17,585	18,341	19,552	19,672	20,625
	Gross margin, %	—	—	—	39.37	39.43	40.80	39.14	40.52	41.71	39.99
	EBT	—	—	—	2,091	2,710	2,875	2,512	2,361	2,581	2,768
	EBT margin, %	—	—	—	12.57	15.79	16.35	13.70	12.08	13.12	13.42
	Net income	—	—	—	1,553	13,897	2,293	1,967	1,614	2,050	2,154
	Depreciation	—	—	—	659	630	625	633	610	580	578
Per share, $
Per share, $	Revenue	—	—	—	36.56	37.72	38.73	40.40	42.97	43.14	45.23
	Earnings	—	—	—	3.35	30.45	5.05	4.22	3.05	4.37	4.56
	Cash flow	—	—	—	4.04	5.75	3.54	4.70	4.62	4.29	4.36
	Capex	—	—	—	(0.61)	(0.53)	(0.51)	(0.67)	(0.85)	(0.88)	(1.06)
	Free cash flow	—	—	—	3.43	5.22	3.03	4.03	3.77	3.41	3.30
	Book value	—	—	—	0.00	32.42	36.73	20.62	15.70	18.56	22.79
	Shares, m	—	—	—	455	455	454	454	455	456	456
Valuation, ×
Valuation, ×	P/E	—	—	—	13.06	13.06	13.06	13.06	25.04	17.89	17.99
	P/S	—	—	—	0.00	0.00	0.00	1.39	1.78	1.81	1.81
	P/B	—	—	—	1.61	1.61	1.61	2.72	4.86	4.21	3.60
	EV/Sales	—	—	—	0.00	0.00	0.00	1.76	2.21	2.20	2.16
	EV/FCF	—	—	—	35.43	35.43	35.43	17.63	25.19	27.82	29.61
Cash, $m
Cash, $m	Operating cash flow	—	—	—	1,838	2,618	1,607	2,134	2,101	1,955	1,987
	Capex	—	—	—	(279)	(243)	(233)	(306)	(386)	(401)	(482)
	Free cash flow	—	—	—	1,559	2,375	1,374	1,828	1,715	1,554	1,505
Balance, $m
Balance, $m	Working capital	—	—	—	—	(628)	239	1,127	429	348	3,396
	Total debt	—	—	—	—	35	37	8,249	10,960	10,472	11,669
	Net debt	—	—	—	—	(972)	(519)	6,804	8,456	7,583	7,157
	Shareholders’ equity	—	—	—	—	14,751	16,676	9,362	7,145	8,464	10,390
Returns, %
Returns, %	ROA	—	—	—	0.00	114.30	8.89	7.12	4.62	6.08	5.95
	ROIC	—	—	—	0.00	12.34	10.81	9.75	9.75	10.22	9.84
	ROE	—	—	—	0.00	0.00	14.30	14.72	16.78	25.54	22.11

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BSX Boston Scientific Corporation	$64.0B	17.9×	17.8×	+7.53% (above 0%: growing)	+14.81% (above 0%: growing)	+13.29% (above 0%: growing)	70.71%	21.65%	Compare
EW Edwards Lifesciences Corporation	$50.8B	49.8×	30.7×	+13.63% (above 0%: growing)	−26.32% (below 0%: shrinking)	+142.84% (above 0%: growing)	77.46%	29.48%	Compare
DXCM DexCom, Inc.	$33.1B	33.2×	29.8×	+13.08% (above 0%: growing)	+41.30% (above 0%: growing)	−11.68% (below 0%: shrinking)	63.44%	24.33%	Compare
GEHC GE HealthCare Technologies Inc.	$31.8B	16.0×	14.4×	+5.75% (above 0%: growing)	+16.98% (above 0%: growing)	+750.00% (above 0%: growing)	41.17%	13.96%
PHG Koninklijke Philips N.V.	$24.9B	18.8×	11.2×	+2.94% (above 0%: growing)	+56.67% (above 0%: growing)	+49.74% (above 0%: growing)	49.31%	13.99%	Compare
STE STERIS plc	$21.9B	27.1×	23.6×	+7.30% (above 0%: growing)	+13.89% (above 0%: growing)	−14.36% (below 0%: shrinking)	45.84%	19.15%	Compare
ZBH Zimmer Biomet Holdings, Inc.	$18.0B	23.0×	17.7×	+4.80% (above 0%: growing)	+33.77% (above 0%: growing)	+13.05% (above 0%: growing)	70.81%	14.98%	Compare
PEN Penumbra, Inc.	$12.7B	78.4×	63.5×	+14.90% (above 0%: growing)	−24.79% (below 0%: shrinking)	+10.81% (above 0%: growing)	67.93%	10.52%	Compare
SNN Smith & Nephew SNATS, Inc.	$12.2B	35.4×	18.6×	+7.99% (above 0%: growing)	−14.23% (below 0%: shrinking)	+293.94% (above 0%: growing)	69.42%	0.00%	Compare
Median of peers	$23.4B	30.2×	21.1×	+7.76%	+14.35%	+13.17%	68.68%	17.07%

All 149 Medical Devices stocks →

GE HealthCare Technologies Inc. (GEHC) key facts

Strength: GE HealthCare Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 billion, up 4.84% from fiscal 2024.
GE HealthCare Technologies Inc. (GEHC) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, GEHC traded at $69.57, a market capitalization of $31.8 billion.
GE HealthCare Technologies Inc. pays an annual dividend of $0.18 per share, a yield of 0.26%, with a payout ratio of 4.13%.
Return on equity was 22.1% and debt-to-equity 1.05.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.96 (grey zone) for fiscal 2025.